Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 10/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459093 | 0.91 | HDAC6 (0.51) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL12459080 | 0.90 | HDAC6 (0.47) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL2362749 | 0.84 | HDAC6 (0.49) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL12459078 | 0.84 | HDAC6 (0.45) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL2361577 | 0.84 | HTR6 (0.54) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3032268 | 0.82 | HDAC6 (0.52) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL2362446 | 0.81 | HTR6 (0.55) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL2362315 | 0.81 | HDAC6 (0.53) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL2361883 | 0.80 | HDAC6 (0.47) | HDAC6HDAC1HTR6HRH1ADRA2A | |
| SCHEMBL12458843 | 0.80 | HDAC6 (0.48) | HDAC6HDAC1HTR6HRH1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2011103430-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HDAC6 2829/4885HDAC1 1343/4885HTR6 48/4885 |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2C, ADRA2B | HDAC6 3060/4885HDAC1 2706/4885HTR6 59/4885 |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | HDAC6 3044/4885HDAC1 4393/4885HTR6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.